Interpace Biosciences Announces Improved Coverage for ThyGeNEXT® and ThyraMIR®
03 mai 2021 08h00 HE
|
Interpace Biosciences, Inc.
Parsippany, NJ, May 03, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today that eviCore Healthcare (“eviCore”), a wholly owned...
Interpace Biosciences Raises Full Year 2021 Revenue Guidance
19 avr. 2021 07h05 HE
|
Interpace Biosciences, Inc.
Parsippany, NJ, April 19, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced an update to its full year 2021 revenue guidance...
Interpace Pharma Solutions Announces New Advanced Offering in RNA Biomarker Analysis
12 avr. 2021 07h05 HE
|
Interpace Biosciences, Inc.
Parsippany, NJ, April 12, 2021 (GLOBE NEWSWIRE) -- Interpace Pharma Solutions, a subsidiary of Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today new capability...
Interpace Biosciences Announces New PLA Code and Medicare Reimbursement Increase for Proprietary Thyroid Assay, ThyGeNEXT®
05 avr. 2021 16h05 HE
|
Interpace Biosciences, Inc.
Parsippany, NJ, April 05, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today that Novitas, its Medicare Administrative Contractor, has...
Interpace Biosciences Announces Contract for Thyroid Testing with Blue Cross Blue Shield of Illinois
25 févr. 2021 16h31 HE
|
Interpace Biosciences, Inc.
In-network status for ThyGeNEXT® and ThyraMIR® with State’s Largest Payer PARSIPPANY, NJ, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or “the Company”), today...
Interpace Biosciences Announces Acceptance for Trading on the OTCQX
24 févr. 2021 17h54 HE
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace Biosciences” or the “Company”), an emerging leader in enabling personalized medicine, today...
Interpace Biosciences Announces License Agreement with Rutgers University and Mass General Hospital
01 févr. 2021 09h27 HE
|
Interpace Biosciences, Inc.
Parsippany, NJ, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) announced today that it has executed a license agreement with Rutgers, The State University of New...
Interpace Biosciences Announces Contract for Thyroid Testing with Blue Cross Blue Shield of Florida
28 janv. 2021 09h15 HE
|
Interpace Biosciences, Inc.
In-network status for ThyGeNEXT® and ThyraMIR® with State’s Largest Payer PARSIPPANY, NJ, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) announced today that the...
Interpace Biosciences Receives Nasdaq Deficiency Notice Due to Delayed Filing of Form 10-Q; No Immediate Impact on Listing
19 nov. 2020 16h11 HE
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (NASDAQ: IDXG) on November 18, 2020 received notice from the Listing Qualifications Staff...
Interpace Biosciences Announces Results of Seminal Clinical Validation Study for Thyroid Assays
26 oct. 2020 06h30 HE
|
Interpace Biosciences, Inc.
Study Demonstrates Superior Performance of ThyGeNEXT® and ThyraMIR® vs. Other Molecular Tests PARSIPPANY, NJ, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG)...